Our skin – a great target for intradermal drug delivery and vaccination
The skin is our first line of defense offering a dense network of immune cells. The dermal layer of the skin is also highly vascularized. Therefore, intradermal injection (i.e. injection in the dermal layer of the skin) offers great benefits for both prophylactic and therapeutic vaccines. Not in the least, the dose-sparing potential of up to 1/10th of the dose for prophylactics compared to other routes of administration like intramuscular. The rich immune network also offers great benefits for therapeutics, including cell-based therapies, clearly in need of boosting the immune response.
Our solution – VAX-ID
VAX-ID® is the heart of Idevax, an ISO13485:2016 certified company. It is an award-winning patented drug delivery device suited for reliable intradermal injection with high ease of use. Devices are currently available for investigational use only (IUO) and research use only (RUO). CE marking and FDA approval are expected by fall 2023.